AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

Why is the FDA regulator returning after ouster? How will Trump's tariffs impact US industries? Why did Intel CEO face calls for resignation? What caused Royal Caribbean waterslide injury? How is AI driving the energy sector boom? Why is McDonald’s CEO worried about customers? What are the effects of rising electric bills?

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

benzinga.com/analyst-stock-ratings/analyst-color/25/08/46805321/abbvie-soars-on-skyrizi-and-rinvoq-strength-outpacing-humira-erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.
Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over…

This story appeared on benzinga.com, 2025-08-01 18:04:50.